PE20230105A1 - Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol - Google Patents
Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadolInfo
- Publication number
- PE20230105A1 PE20230105A1 PE2022001894A PE2022001894A PE20230105A1 PE 20230105 A1 PE20230105 A1 PE 20230105A1 PE 2022001894 A PE2022001894 A PE 2022001894A PE 2022001894 A PE2022001894 A PE 2022001894A PE 20230105 A1 PE20230105 A1 PE 20230105A1
- Authority
- PE
- Peru
- Prior art keywords
- tapentadol
- dosage form
- phosphoric acid
- acid salt
- form providing
- Prior art date
Links
- 229960005126 tapentadol Drugs 0.000 title abstract 7
- 239000002552 dosage form Substances 0.000 title abstract 3
- -1 TAPENTADOL PHOSPHORIC ACID SALT Chemical class 0.000 title 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 abstract 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 235000010980 cellulose Nutrition 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 150000003016 phosphoric acids Chemical class 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDO A UNA FORMA DE DOSIFICACION FARMACEUTICA DE LIBERACION PROLONGADA QUE COMPRENDE TAPENTADOL PARA SU ADMINISTRACION ORAL DOS VECES AL DIA, EN DONDE EL TAPENTADOL ESTA PRESENTE COMO UNA SAL CON ACIDO FOSFORICO TAL COMO DIHIDROGENOFOSFATO DE TAPENTADOL, Y EN DONDE EL TAPENTADOL SE INCORPORA A UNA MATRIZ DE LIBERACION PROLONGADA QUE CONSISTE EN HIDROXIPROPILMETILCELULOSA (HPMC), HIDROXIPROPILCELULOSA (HPC), HIDROXIETILCELULOSA (HEC), CELULOSA MICROCRISTALINA, ENTRE OTROS. LA DOSIS EQUIVALENTE EN PESO DE TAPENTADOL CONTENIDA EN LA FORMA DE DOSIFICACION FARMACEUTICA SE ENCUENTRA DENTRO DEL INTERVALO DE 10 A 300 MG EN BASE A LA BASE LIBRE DE TAPENTADOL.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20160419.6A EP3875077B1 (en) | 2020-03-02 | 2020-03-02 | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| EP20160420.4A EP3875079A1 (en) | 2020-03-02 | 2020-03-02 | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| PCT/EP2021/055025 WO2021175773A1 (en) | 2020-03-02 | 2021-03-01 | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230105A1 true PE20230105A1 (es) | 2023-01-25 |
Family
ID=74701506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001894A PE20230105A1 (es) | 2020-03-02 | 2021-03-01 | Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4003318A1 (es) |
| BR (1) | BR112022017700A2 (es) |
| CO (1) | CO2022012567A2 (es) |
| DE (1) | DE202021003994U1 (es) |
| MX (1) | MX2022010780A (es) |
| PE (1) | PE20230105A1 (es) |
| WO (1) | WO2021175773A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022017700A2 (pt) | 2020-03-02 | 2023-01-17 | Gruenenthal Gmbh | Forma de dosagem fornecendo liberação prolongada de sal de ácido fosfórico de tapentadol |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL88083A (en) * | 1987-11-06 | 1992-11-15 | Tanabe Seiyaku Co | Controlled release pharmaceutical dosage form and its preparation |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| PE20030527A1 (es) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| ES2429436T3 (es) * | 2002-02-21 | 2013-11-14 | Otsuka Pharmaceutical Co., Ltd. | Preparaciones de liberación lenta y procedimiento para la producción de las mismas |
| PL1786403T3 (pl) | 2004-07-01 | 2013-10-31 | Gruenenthal Gmbh | Doustna postać dawki zabezpieczona przed nadużywaniem zawierająca (1R, 2R)-3-(3-dimetyloamino-1-etylo0-2-metylo-propylo)fenol |
| CN101568329A (zh) | 2006-10-27 | 2009-10-28 | 詹森药业有限公司 | 干燥颗粒药用组合物及其生产方法 |
| AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
| PE20190391A1 (es) | 2008-10-30 | 2019-03-13 | Gruenenthal Chemie | Formas de dosificacion del tapentadol novedosas y potentes |
| DK3656765T3 (da) | 2010-07-23 | 2021-06-14 | Gruenenthal Gmbh | Salte eller co-krystaller af 3-(3-dimethylamin-1-ethyl-2-methyl-propyl)-phenol |
| WO2012051246A1 (en) | 2010-10-12 | 2012-04-19 | Ratiopharm Gmbh | Tapentadol hydrobromide and crystalline forms thereof |
| CN105682643B (zh) | 2013-07-12 | 2019-12-13 | 格吕伦塔尔有限公司 | 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型 |
| US20160136112A1 (en) | 2013-08-02 | 2016-05-19 | Ratiopharm Gmbh | Composition comprising tapentadol in a dissolved form |
| EP2942054A1 (en) | 2014-05-09 | 2015-11-11 | G.L. Pharma GmbH | Slow-release pharmaceutical formulation |
| ES2937740T3 (es) | 2016-04-19 | 2023-03-30 | Ratiopharm Gmbh | Fosfato de tapentadol cristalino |
| EP3630074B1 (en) | 2017-05-29 | 2023-10-25 | Grünenthal GmbH | Multiparticulate oral dosage form providing prolonged release of tapentadol |
| BR112022017700A2 (pt) | 2020-03-02 | 2023-01-17 | Gruenenthal Gmbh | Forma de dosagem fornecendo liberação prolongada de sal de ácido fosfórico de tapentadol |
-
2021
- 2021-03-01 BR BR112022017700A patent/BR112022017700A2/pt unknown
- 2021-03-01 EP EP21707730.4A patent/EP4003318A1/en active Pending
- 2021-03-01 WO PCT/EP2021/055025 patent/WO2021175773A1/en not_active Ceased
- 2021-03-01 MX MX2022010780A patent/MX2022010780A/es unknown
- 2021-03-01 DE DE202021003994.5U patent/DE202021003994U1/de active Active
- 2021-03-01 PE PE2022001894A patent/PE20230105A1/es unknown
-
2022
- 2022-09-02 CO CONC2022/0012567A patent/CO2022012567A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022017700A2 (pt) | 2023-01-17 |
| MX2022010780A (es) | 2022-09-26 |
| WO2021175773A1 (en) | 2021-09-10 |
| EP4003318A1 (en) | 2022-06-01 |
| CO2022012567A2 (es) | 2022-09-09 |
| DE202021003994U1 (de) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2482104T3 (es) | Formulaciones HRT | |
| EA201590449A1 (ru) | Перорально вводимая лекарственная композиция | |
| CY1109910T1 (el) | Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων | |
| KR20230145525A (ko) | 과다 졸림증을 치료하기 위한 방법 및 조성물 | |
| AR059723A2 (es) | Composicion de altas dosis de ibandronato | |
| JP2019131588A5 (ja) | 抗そう痒剤 | |
| US20240325332A1 (en) | Bactericidal and virucidal pharmaceutical composition | |
| CO5410187A1 (es) | Formulacion oral de dosis unica de espinosad | |
| PE20230105A1 (es) | Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol | |
| BR122021012549B8 (pt) | Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva | |
| AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
| AR065816A1 (es) | Regimen anticonceptivo oral | |
| MX2019008482A (es) | Tratamiento medico que comprende administracion enteral de edaravona. | |
| TWD207946S (zh) | 藥物輸送裝置 | |
| RU2006137329A (ru) | Распадающиеся таблетки, содержащие ликарбазепин | |
| AR129190A1 (es) | Nuevo uso médico de la tafoxiparina | |
| CN110833540B (zh) | 一种柳酚咖敏片及其制备方法 | |
| PE20240241A1 (es) | Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo | |
| PE20221446A1 (es) | Nuevas formulaciones de comprimido de fosfomicina | |
| CN102488688A (zh) | 以黄藤素为主药的眼用制剂 | |
| CN103301063A (zh) | S（+）-氟比洛芬酯注射乳剂 | |
| PE20240113A1 (es) | Formas de dosificacion de liberacion sostenida de una sal de tapentadol con acido l-(+)-tartarico | |
| CO2025003053A2 (es) | Composiciones farmacéuticas sólidas de adagrasib | |
| CL2024004086A1 (es) | Composición farmacéutica sólida de liberación inmediata que comprende pregabalina, proceso de preparación y uso. | |
| DOP2024000193A (es) | Combinación de celecoxib - acetaminofén de estabilidad mejorada y procedimiento para su preparación |